Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Virological cure at day 5 15% Improvement Relative Risk HCQ for COVID-19  Shabrawishi et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 93 patients in Saudi Arabia No significant difference in viral clearance Shabrawishi et al., medRxix, May 2020 Favors HCQ Favors control

Negative nasopharyngeal SARS-CoV-2 PCR conversion in response to different therapeutic interventions

Shabrawishi et al., medRxix, doi:10.1101/2020.05.08.20095679
May 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 93 hospitalized patients in Saudi Arabia showing a non-statistically significant 15% reduction in PCR positive results at day 5, RR 0.85, p = 0.65. The treatment group had significantly more severe illness and significantly more male patients.
Although the viral clearance result is not statistically significant, it is consistent with the significant 20% improved viral clearance [10‑28%] from meta analysis of the 44 viral clearance results to date.
risk of no virological cure at day 5, 14.7% lower, RR 0.85, p = 0.66, treatment 12 of 45 (26.7%), control 15 of 48 (31.2%), NNT 22.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Shabrawishi et al., 11 May 2020, retrospective, Saudi Arabia, preprint, mean age 43.9, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Negative nasopharyngeal SARS-CoV-2 PCR conversion in Response to different therapeutic interventions
Mohammed Hassan Shabrawishi, Abdallah Y Naser, Hassan Alwafi, Ahmad Mansoor Aldobyany, Abdelfattah Ahmed Touman
Take home message: Prescribing antimalarial medications for patients with COVID-19 was not shown to shorten the disease course nor to accelerate the negative PCR conversion rate.
CONFLICT OF INTEREST The authors have stated explicitly that there are no conflicts of interest in connection with this article. AUTHORS CONTRIBUTIONS Shabrawishi, Naser, Touman, and Alwafi had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Shabrawishi, and Touman had the original idea for this study. Shabrawishi, Naser, Touman, and Alwafi contributed to the design of the study. Shabrawishi and Touman contributed to the data collection. Naser
Bai, Yao, Wei, Tian, Chen, Presumed Asymptomatic Carrier Transmission of COVID-19, JAMA
Chen, Liu, Liu, Liu, Xu et al., A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J of Zjeijang University
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet
Chorin, Dai, Shulman, Wadhwani, Cohen et al., The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin
Colson, Rolain, Lagier, Brouqui, Raoult, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents
Colson, Rolain, Raoult, Chloroquine for the 2019 novel coronavirus SARSCoV-2
Ferner, Aronson, Chloroquine and hydroxychloroquine in covid-19, BMJ
For, Control, Information for Clinicians on Investigational Therapeutics for Patients with COVID-19 2020
Gautret, Lagier, Parola, Hoang, Meddeb et al., Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study, Travel Med Infect Dis
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label nonrandomized clinical trial, Int J Antimicrob Agents
Gunja, Roberts, Mccoubrie, Lamberth, Simes, Survival after massive hydroxychloroquine overdose, Anaesth Intensive Care
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov
Magagnoli, Narendran, Pereira, Cummings, Hardin et al., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19
Makin, Wendon, Fitt, Portmann, Williams, Fulminant hepatic failure secondary to hydroxychloroquine, Gut
Murphy, Carmichael, Fatal toxic epidermal necrolysis associated with hydroxychloroquine, Clin Exp Dermatol
Rothe, Schunk, Sothmann, Bretzel, Froeschl et al., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany, N Engl J Med
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Yao, Ye, Zhang, Cui, Huang et al., Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop